Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Homatropine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 1.00 |
| ▸ | CHRM3 known ✓ | P20309 | 6/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.68 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.68 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.68 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.62 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.55 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.55 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.55 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.55 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Homatropine SCHEMBL41951 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Homatropine SCHEMBL23969 | 0.99 | LMNA (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Homatropine SCHEMBL9653008 | 0.99 | LMNA (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Homatropine SCHEMBL23970 | 0.99 | LMNA (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Homatropine SCHEMBL15275620 | 0.99 | LMNA (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Homatropine SCHEMBL23468168 | 0.99 | LMNA (1.00) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Homatropine SCHEMBL220964 | 0.97 | LMNA (0.97) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Homatropine SCHEMBL220965 | 0.97 | LMNA (0.97) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Homatropine SCHEMBL14672464 | 0.96 | LMNA (0.95) | CHRM2CHRM1CHRM3CHRM5CHRM4 | |
| Homatropine SCHEMBL10743457 | 0.96 | LMNA (0.95) | CHRM2CHRM1CHRM3CHRM5CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1397 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024240216-A1 | PHARMACEUTICAL COMPOSITION FOR EFFECTIVELY DELAYING AND TREATING MYOPIA | 温州医科大学附属眼视光医院 | 2024-11-28 | — | — | WO | claimed |
| US-20230059938-A1 | PHARMACEUTICAL FORMULATION FOR INHIBITING BODY MALODOUR | National Skin Centre (Singapore) Pte Ltd (SG) | 2023-02-23 | — | — | US | claimed |
| CN-114760997-A | Pharmaceutical preparation for inhibiting body odor | 全国皮肤中心 | 2022-07-15 | — | — | CN | claimed |
| CN-114414679-A | Method for detecting belladonna alkaloid in animal tissue | 吉林省农业科学院 | 2022-04-29 | — | — | CN | claimed |
| CN-108797142-B | Preparation method of moisture-absorbing, antibacterial and water vapor permeable graphene modified polyurethane synthetic leather | 浙江英飞实业有限公司 | 2021-09-21 | — | — | CN | claimed |
| WO-2021118465-A1 | A PHARMACEUTICAL FORMULATION FOR INHIBITING BODY MALODOUR | National Skin Centre (Singapore) Pte Ltd (SG) | 2021-06-17 | — | — | WO | claimed |
| CN-110699972-A | Antibacterial wear-resistant synthetic leather, preparation method and equipment | 清远市齐力合成革有限公司 | 2020-01-17 | — | — | CN | claimed |
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | NANOEGG RESEARCH LABORATORIES, INC. (JP) | 2019-05-02 | — | — | US | claimed |
| EP-3456353-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | Nanoegg Research Laboratories, Inc. (JP) | 2019-03-20 | — | — | EP | claimed |
| CN-108914564-A | Preparation method of moisture-absorbing, breathable and antibacterial spunlace non-woven fabric for polyurethane synthetic leather | 段小宁 | 2018-11-30 | — | — | CN | claimed |
| WO-1997000669-A1 | COMPOSITIONS AND METHODS FOR STABILIZING POLYMERS | NOVARTIS AG (CH) | 1997-01-09 | — | — | WO | claimed |
| EP-0652774-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER. | PROCTER & GAMBLE (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0608320-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0608322-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| WO-1994002176-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| CN-1072863-A | Be used to improve the dermal osmosis system of the reinforcement of medicine localized delivery | RICHARDSON VICKS INC (US) | 1993-06-09 | — | — | CN | claimed |
| CN-1072602-A | Improve the enhanced dermal osmosis system of the local conveying of medicine | RICHARDSON VICKS INC (US) | 1993-06-02 | — | — | CN | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1993007903-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125734-A1 | COMPOSITION FOR TREATING OR PREVENTING ATOPIC DERMATITIS | CHRM3, ACHE, CHRNB1 | CHRM2 5/4885CHRM3 1/4885ADRA2C 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.